-->

Company Registry

Nangiotx Inc
Profile last edited on: 8/10/2020

Treatment for peripheral artery disease
Year Founded
2015
First SBIR Year
2019
Latest SBIR Award
2020
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

555 Fifth Avenue - 17th Floor
New York, NY 10011
   (678) 613-1386
   vivek@nangiotx.com
   www.nangiotx.com
Multiple Locations:   
Congressional District:   10
County:   Essex

Public Profile

Nangiotx Inc. is developing technology to treat peripheral artery disease (PAD). There are 8 million Americans living with PAD. In these patients, obstructed arteries result in poor blood flow (ischemia) to cardiac and peripheral tissues, and manifests in pain with walking (intermittent claudication). Prolonged ischemia inhibits wound healing, starves the muscles of oxygen and nutrients, and causes muscle wasting (atrophy) or cell death (necrosis). Given the high rate of surgical failure, the inevitable prognosis for advanced stage PAD (critical limb ischemia, CLI) is amputation (at 30%) and death (at 25%). NangioTx has a unique approach to treating PAD that is based on molecular mimicry of the body’s natural mechanism for blood vessel generation. The process is mediated by the engagement of the Vascular Endothelial Growth Factor (VEGF) to its cognate receptors (VEGFR). Towards this end, NangioTx has licensed “V-10”, the lead self-assembling peptide mimic of VEGF (otherwise known as the QK domain) for inducing angiogenesis and treating poor blood flow in PAD. V-10 was developed through 10+ years of research at Rice University, and consists of a novel multi-domain sequence of 31 amino acids, with each of the domains serving a unique purpose. V-10 is easily produced by solid phase peptide synthesis, and its shelf life at room temperature is longer than a year in a standard laboratory environment.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Key People / Management

  Marwa Choudhury --

SBIR firms in the news

There are no news available.